Podcasts about MBC

[장경태 더불어민주당 의원]최민희 논란? 국감 파행 자극적 기사에 항의언론 적 만든다? 개혁 과정의 성장통김민수 발언? 中 자본 국내 투자 2% 뿐 부동산 정책, 공급 확대 방안 힘 실어야 [김종혁 국민의힘 前 최고위원]MBC, 막장 국감 비판한 것 뿐...최민희 논란尹 몰락 시작점, '바이든-날리면' 보도 공방외국인 투자, 美 돈은 괜찮고 中은 안되나?이상경, 국민 염장 그만 지르고 사퇴해야 ■ 방송 : CBS 라디오 [김현정의 뉴스쇼] FM 98.1 (07:10~09:00)■ 진행 : 김현정 앵커■ 대담 : 장경태(더불어민주당 의원), 김종혁(국민의힘 前 최고위원)See omnystudio.com/listener for privacy information.

Janice Cowden, retired nurse and patient advocate, shares her remarkable triple negative breast cancer (TNBC) story. Five years following successful treatment for stage one breast cancer in 2011, Janice was diagnosed with a stage 4 metastatic TNBC recurrence. As of today she has 8 years of no evidence of disease (NED) under her belt. She shares how she stumbled upon the cancer community that inspired her to become the advocate she is today and the uncertainty that comes with NED. She also shares how she copes with losing friends in the cancer community through her patient advocacy work. We also have a rapid fire Q&A where she answers questions surrounding various medical terminologies, diagnoses, and more to keep you in the loop. NOTE: There is one clarification from the rapid fire Q&A session. The definition of disease free survival (DFS) is the time from random assignment (used in clinical trials and research studies to assign participants to different groups) to cancer recurrence or death from any cause (Gutman SI, Piper M, Grant MD, et al. 2013).Key Highlights:1. Metastatic breast cancer (MBC) is stage four breast cancer that has spread to distant sites in the body.2. Finding events and communities centered around cancer not only supports cancer patients emotionally and socially, but can also serve as informational hubs. Being proactive in learning about your diagnosis, whether it's through community and/or research on your own time, can help you feel confident with the choices you make. 3. While finding a community of other cancer patients can help, unfortunately this disease means that you will lose friends you make in these settings. It doesn't necessarily get easier, but finding an outlet to cope with such losses is vital to your wellbeing.About our guest:Diagnosed with Stage IV triple negative breast cancer in 2016, five years after an early-stage breast cancer diagnosis, Janice launched into patient advocacy following training through Living Beyond Breast Cancer's (LBBC) Hear My Voice Outreach program in 2017. As a peer-to-peer support and research patient advocate, Janice is passionate about supporting others with metastatic breast cancer, in addition to continually furthering her scientific knowledge base of this disease, treatments, and clinical trials, which she acquires through attending scientific breast cancer conferences and webinars. Janice is involved with several patient-founded and led organizations including PCDI, GRASP, and Project Life MBC. As a trained peer support volunteer, she is founder of an international online peer support group for patients newly diagnosed with MBC. She serves on the Board of Directors for METAvivor Research and Support Inc., and is an Advisory Board member for Project Life MBC. She is an individual member of the Metastatic Breast Cancer Alliance. When she's not busy with advocacy work, Janice enjoys traveling, reading, outdoor activities, and spending time with family, including her husband, two adult children and three grandchildren.Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions.

1-2부 [뉴스신세계] 1. 미중 정상 국빈방한…29일 한미·11월 1일 한중 연쇄회담 2. '채상병 순직' 임성근 구속…'수사외압' 이종섭 영장 기각 3. 정청래 “오세훈 끝났다”…오세훈 “제 일은 제가 알아서” - MBC 이정은 기자 (출연) [이슈하이킥] 10.15 대책 충격과 보유세 논란…흔들리는 부동산 시장 진단 - 권대중 한성대 일반대학원 경제부동산학과 석좌교수 - 김인만 김인만부동산경제연구소장 (출연)

◎ 1부 [뉴스 연구소] 부동산 민심, 사과한 민주당/ 캄보디아 로맨스 스캠 부부, 대사관이 풀어줬다/ 딴지일보에 글 쓴 정청래 경향신문 박순봉 기자, 김준일 시사 평론가 [월간] 김건희, ‘용상’ 착석 논란/ 김현지, 국감 불출석?/ 최민희, MBC보도본부장 퇴장 지시/ 이상영 1차관, 발언 논란 더불어민주당 박지원 의원 ◎ 2부 [놓지마 뉴스] 방송인 강승희 [인터뷰 (1)] 사법·검찰·언론 3대 개혁안 평가/ 尹 면회 찾아간 장동혁 조갑제 조갑제닷컴 대표 [인터뷰 (2)] 10만 전자, 50만 닉스/ 2차 전지 주가 급등/ 금값은 폭락, 왜? AFW파트너스 이선엽 대표 [미니 댓꿀쇼] 지방선거 판세 분석 조갑제 조갑제닷컴 대표 See omnystudio.com/listener for privacy information.

251023(1) [뉴스브리핑 아침 배송] (1) 국정자원 화재, 결국 '인재'였나…"불법 하도급업체가 공사" / (2) 서울 15개 구청장, 10·15 대책에 "토지거래허가구역 지정 즉각 철회" / (3) 정보위, 캄보디아 범죄 국정원 현안보고 / (4) 與 문체위 "김건희, 경복궁 '용상'에 왜 앉았냐" / (5) MBC 보도본부장 비판 / (6) 김건희 특검기소 3차 공판 - 김완

1-2부 [뉴스신세계] 1. 李 "사정기관이 국가질서 어지럽혀…엄정히 단죄해야" 2. 이상경 국토부 차관 사과...“국민 눈높이 못 미쳐” 3. 이종섭·임성근 오늘 구속 갈림길…해병특검 '운명의 날' - MBC 이정은 기자 (출연) [이슈하이킥1] ‘연어 술파티' 의혹, 진실은 무엇인가 - 봉지욱 기자 (출연)

How do you know if your child is making progress in therapy? What if therapy came with a GPS that showed you exactly where your child is on their mental health journey and the best route to reach their goals? In this episode, we explore measurement-based care (MBC) with CHC experts Pardis Khosravi, PsyD and Emily Hsu, PhD – about this approach that's transforming mental health treatment by making progress visible and treatment more effective.Join us as we break down this game-changing practice that combines regular progress tracking with personalized care. We'll discover why MBC matters for everyone – not just clinicians – and how simple questionnaires and check-ins can dramatically improve the therapy experience.Resources:CHC OnlineCHC's Catherine T. Harvey Center for Clinical ServicesCHC's Resource LibrarySign up for our Virtual Village email list to receive our latest episodes and recent CHC updates. Visit Voices of Compassion online for full show notes including additional resources. Find us on Facebook, Twitter, Instagram and LinkedIn and visit our YouTube channel for videos. Subscribe and leave us a review wherever you listen! We love to hear from you - email us at podcast@chconline.org.Santo Rico by Twin Musicom is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/Artist: http://www.twinmusicom.org/

[고민사연] 안녕하세요? MBC 라디오 미니로 손경제 청취하는 40대 직장인입니다. 올해 이직해서 근무 중인데 회사 사정 상 폐업을 한다는 얘기를 들었습니다. 이직한지 1년이 안되었는데, 회사가 없어지면 퇴직금을 받을 수 있는건가요.? 회사가 문을 닫게되면 어디로 가서 어떻게 퇴직금을 달라고 해야하는지도 궁금합니다. 참고로, 저희 회사는 증권사에 DB형 퇴직연금이 가입되어 있고, 폐업은 연내에 이뤄질 것 같다고 합니다. 회사 폐업도 걱정이긴 하지만, 다시 이직할 일도 걱정입니다.

Featuring perspectives from Dr Aditya Bardia and Dr Adam M Brufsky, including the following topics: Introduction: Antibody-drug conjugates in localized breast cancer (0:00) Case: A frail woman in her late 70s with ER-positive, HER2-low metastatic breast cancer (mBC) receives sacituzumab govitecan after multiple lines of therapy — Eric Fox, DO (7:46) Case: A woman in her early 60s with NTRK-mutant ER-negative, HER2-low recurrent mBC receives trastuzumab deruxtecan — Lai (Amber) Xu, MD, PhD (21:07) Case: A woman in her mid 70s with PIK3CA-mutant recurrent metastatic triple-negative breast cancer who developed a diverticular abscess on neoadjuvant chemoimmunotherapy receives sacituzumab govitecan and pembrolizumab — Alan B Astrow, MD (31:49) Case: A woman in her mid 60s with ER-negative, HER2-low mBC receives sacituzumab govitecan after experiencing disease progression on capecitabine — Laila Agrawal, MD (38:37) Case: A woman in her late 50s with ER-negative, HER2-low mBC receives trastuzumab deruxtecan after experiencing disease progression on sacituzumab govitecan — Kimberly Ku, MD (44:24) Case: A woman in her early 60s with ER-positive, HER2-low mBC and hyperglycemia receives trastuzumab deruxtecan after experiencing disease progression on capivasertib/fulvestrant — Eleonora Teplinsky, MD (48:50) CME information and select publications

سامح سند هو صانع محتوى مصري ومخرج تلفزيوني سابق، بدأ مسيرته كصحفي بعد تخرّجه من كلية الآداب قسم إعلام شعبة صحافة، ودرس الإخراج السينمائي في قصر ثقافة السينما. شغل منصب Senior Producer في قناة النهار، وعمل مع عدد من القنوات مثل DW الألمانية، روتانا، روتانا مصرية، وقناة الساعة الليبية. أخرج برامج ناجحة أبرزها "جمعة مفيدة" و"مع منى الشاذلي" على MBC، كما عمل رسّام كاريكاتير في جريدة "الوفد" وتعلّم على يد جمعة فرحات. في عام 2014، سافر إلى الولايات المتحدة لدراسة صناعة الأفلام الوثائقية، وهناك اكتشف تحوّل الجمهور عن التلفزيون إلى المحتوى الرقمي. قرر ترك العمل التلفزيوني عام 2018 وبدأ رحلته كمحتوى مستقل على الإنترنت بدعم من زوجته. رغم التحديات المالية التي واجهته في البداية، نجح في ترسيخ أسلوب سردي خاص به، يجمع بين التحقيق، الدراما، والتحليل النفسي، ويعتمد على اللغة العربية الفصيحة والتقنيات الحديثة كالذكاء الاصطناعي في تصميم الصور البصرية. أصدر كتابًا بعنوان "أغرب الحكايات"، والذي يوثق فيه بعضًا من أغرب وأعمق القصص الحقيقية التي تناولها بمزيج من التحليل والخيال، مثل قصة "داهش والطريقة الداهشية". يطوّر حاليًا مشروعًا مسرحيًا بعنوان "مسرح الجريمة"، يُعاد فيه تمثيل جرائم حقيقية أمام الجمهور الذي يشارك في فك لغز الجريمة على خشبة المسرح، ويستعد أيضًا لخوض تجربة جديدة في مع مجدي الهواري لتحويل رواياته الى عمل درامي.Produced by: Abbas Aboelhassan Follow: rwa.podcast.eg Instagram: https://www.instagram.com/rwa.podcast.eg/ Facebook: https://web.facebook.com/rwa.podcast.eg Twitter: https://twitter.com/rwa_podcast_eg Tiktok: https://www.tiktok.com/@rwa.podcast.eg Follow Abbas Aboelhassan: Instagram: https://www.instagram.com/abbasaboelhassanofficial/ Facebook: https://web.facebook.com/Abbasyz Follow Sameh Sanad: Facebook: https://www.facebook.com/POVsamehsanad Instagram: https://www.instagram.com/samehsanad/ Listen to our podcast: https://www.buzzsprout.com/1248233 

Bienvenue dans le 128ème épisode de "Chez Kevin Razy". Deux fois par semaine, on se retrouve ici pour parler de ce qui se passe dans la vie comme dans un groupe WhatsApp. On ne s'interdit aucun sujet.Pour soutenir notre podcast :https://fr.tipeee.com/ckr-podcast/Rejoins notre canal Telegram :https://t.me/CKRnews▬▬▬▬▬▬ DANS CET EPISODE ▬▬▬▬▬▬▬Cette semaine, on revient sur :La petite news HMD (HAMDOULILAH)➡️ DARMANIN VERSION 2.0 :Le ministre de l'Intérieur annonce que les victimes seront désormais informées quand leur agresseur sortira de prison.Une mesure qui, sur le papier, paraît logique… sauf quand on se souvient que la Cour de cassation a confirmé le non-lieu pour l'affaire de viol qui le visait.Bienvenue dans la République de l'absurde.Au menu :ISRAËL TUE UN ENFANT DE 11 ANS.Mohammed Al-Hallaq, abattu par des soldats israéliens alors qu'il jouait au foot à Hébron.Les bombardements ont repris au Liban — officiellement contre le Hezbollah, officieusement contre les civils.BEN LE PATRIOTE DE LA DIVERSITÉUn influenceur musulman qui pensait pouvoir rallier les fachos. Spoiler : ils ne veulent pas de lui.Jean Messiha, MBC et compagnie l'ont recalé.

1-2부 [뉴스신세계] 1. 이상민 "계엄 명확히 반대해"…재판서 혐의 전부 부인 2. 21그램 대표 실토 "한남동 관저에 히노키탕·다다미 설치" 3. 혁신당 '조희대 탄핵안' 공개…"대선개입 판결·헌법질서 훼손" - MBC 이정은 기자 (출연) [이슈하이킥] 잇단 구속영장 기각… 내란특검과 검찰개혁, 어디로 가나? - 류혁 전 법무부 감찰관 (출연)

1-2부 [뉴스신세계] 1. 대법, 최태원-노소영 재산분할 파기환송...…盧비자금 불인정 2. 국감 나흘째 '법사위·과방위' 파행…고성·욕설 논란 지속 3. 10.15 부동산 시행 첫날...여야 등 각계 반응은? - MBC 이정은 기자 (출연) [주간정치동형] 김현지 논란부터 YTN 매각 의혹까지… 국감 핵심은? - 이동형 작가 (출연)

Tabitha Holman was diagnosed at 39 with de novo Stage IV breast cancer. Tabitha is an elementary school teacher, and mother of two young boys. At the time of her diagnosis, she was considered too young and low-risk to access a timely mammogram when she found her lump. Now she is focusing her efforts on advocacy in hopes of improving access to screening, research, and care. In this episode, Tabitha reads her essay “Hair Karma” from the 2025 Hair issue of Wildfire Journal. Her piece is about the emotional complexity of losing her hair during chemotherapy—just months after giving birth—and the surprising, full-circle moment that made her stop and wonder. April and Tabitha will talk about kindness, having cancer and being post-partum, and advocating for medical care that goes against the standard of care. They also discuss grief and living with MBC. More about episode sponsor After Breast Cancer Diagnosis (ABCD): https://abcdbreastcancersupport.org/Learn more about Tabitha: https://www.instagram.com/tabitha.arise/Purchase the “Hair” issue of Wildfire Journal: https://www.wildfirecommunity.org/shop/p/digital-hair25Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860Get the free Wildfire “Hot Flashes” email newsletter: https://www.wildfirecommunity.org/newsletter?rq=newsletterLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shop*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeMore about Wildfire Journal: https://www.wildfirecommunity.orghttps://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunityInformation on submitting your story for consideration to be published in Wildfire Journal: https://www.wildfirecommunity.org/submissions

Featuring an interview with Dr Laura Huppert, including the following topics: General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00) Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44) Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30) Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13) Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25) CNS penetration and activity of ADCs in the treatment of breast cancer (22:27) Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24) Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05) Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51) Ongoing evaluation of ADCs in the localized disease setting (35:42) Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38) CME information and select publications

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy for these patients. Supported by an educational grant from Lilly.Faculty:Manali Bhave, MDMedical Director, Phase I Clinical Trials UnitAssistant ProfessorDepartment of Hematology and OncologyWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaErin F. Cobain, MDAssociate Professor of Internal MedicineDivision of Hematology/OncologyBreast Oncology ProgramUniversity of Michigan Rogel Cancer CenterAnn Arbor, Michigan Link to obtain CME/CE credit:https://bit.ly/4nUJO1OLink to Oncology Breast Cancers with additional educational activities:https://bit.ly/4nNGlBY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this raw, funny, and beautifully honest episode, Wren, the founder of the Living Our Breast Lives Podcast, is joined by the vibrant Annie Bond—a woman who's not just living with Metastatic Breast Cancer, but marking an incredible 10 years of thriving with it. Annie invites us beyond the diagnosis and into her world: her advocacy, her comedy, her social media voice, and her unapologetic authenticity.We dive into the realities of MBC—from the milestone of a decade with the disease to the heartbreak of a recent breakup and painful losses we experience so often in this community. Annie shares how she uses dark humor and creativity to cope, how advocacy keeps her grounded, and why building authentic connections—online and in person—has been one of the greatest gifts of this journey.She also opens up about the balance between laughter and grief, joy and sorrow, and why honesty matters more than toxic positivity ever could. Through it all, Annie reminds us that even in the hardest spaces, community and truth-telling can carry us forward.Whether you're living with MBC, love someone who is, or just want to hear a bold and unfiltered story of resilience, humor, and heart—this episode is for you. It's real, it's raw, and it's proof that even in the face of stage four, life can still be loud, messy, meaningful—and full of laughter.Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrAnnie Bond's Information:@theanniebond on FB, IG, and TikTok

[뉴스신세계] 1. '내란종사' 박성재 영장 청구‥특검 다시 속도 2. 국힘, 상황실 가동하며 국감체제 전환…"실정 고발·대안 제시" 3. 국힘, ‘중국인 3대 쇼핑 방지법' 당론 추진한다 - MBC 이정은 기자(출연) [이슈하이킥1] 민주당, 서울시장 탈환 가능할까? - 더불어민주당 박주민 의원 (출연)

This episode is all about the purisuit to understand and treat metastatic breast cancer. Dr. Martine Piccart and Dr. Lisa Carey delve into the complexities of metastatic breast cancer (MBC), highlighting why it remains one of the most challenging forms of the disease to treat.

1-2부 [뉴스 신세계] 1. 李대통령 부부 '냉부해' 방영 뒤 계속되는 공방 2. 장동혁 '건국전쟁2 관람' 후폭풍...4·3유족들 분노 3. 대통령실, 한미통상 대책회의…APEC 앞두고 협상 총력전 -MBC 이정은 기자 (출연) [거침없이 하이킥] 추석 민심부터 내년 지방 선거까지…정치권 최대 화두는 - 신인규 변호사 - 장성철 공론센터 소장 (출연)

Send us a textIn our Season 11 opening episode, we're bringing you the latest updates from the 2025 ASCO Annual Meeting on metastatic breast cancer. Dr. Ashley Schreier, breast oncologist at Weill Cornell Medicine, breaks down key research and explains what it could mean for people living with MBC.Topics include:Research results for hormone therapy options like camizestrantThe role of ESR1 mutation testingResults from treatment combinations like Enhertu and Perjeta, and Trodelvy and KeytrudaHow to navigate clinical trial accessTips for staying hopeful while exploring treatment optionsWhether you're a patient, caregiver, or advocate, this episode is packed with insights to help you stay informed and empowered.

A fuel price hike, a new cabinet, MBC resistance, the public sector gender gap, Mpox cases, and much more! Thanks for tuning in!Let us know what you think and what we can improve on by emailing us at info@rorshok.com. You can also contact us on Instagram @rorshok_malawi or Twitter @RorshokMalawiLike what you hear? Subscribe, share, and tell your buds.We want to get to know you! Please fill in this mini-survey: https://forms.gle/NV3h5jN13cRDp2r66Wanna avoid ads and help us financially? Follow the link: https://bit.ly/rorshok-donate

Beidh an chéad troid ghairmiúil ag bean Chill na Martra ar an Aoine sa Staid Náisiúnta i mBÁC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

1-2부 [뉴스 신세계] 1. 이진숙, 법원에 체포적부심 청구...4일 오후 심문 2. 국가전산망 장애 담당 공무원 세종청사서 투신 사망 3. MBC 여론조사...李 긍정평가 59% 부정평가 33%[코리아리서치] -MBC 이정은 기자 (출연) [이슈하이킥1] 방미통위 출범, 방송개혁 제대로 이뤄질까? - 더불어민주당 최민희 의원 (출연)

1-2부 [뉴스신세계] 1. 경찰, '선거법 위반 혐의' 이진숙 체포 2. 법원, '체포 방해' 윤석열 보석 기각…구속 상태 유지 3. 김건희, 종묘 차담회 때 비공개 성역 ‘신실'도 구경했다 - MBC 이정은 기자 (출연) [거침없이 하이킥] 여야 종교단체 동원 의혹, 정치권 어디까지 번질까? - 신인규 변호사 - 장성철 공론센터 소장 (출연)

Today, we welcome Tami Eagle Bowling — motivational speaker and advocate for #LightUpMBC, a global event illuminating landmarks and amplifying patient voices. The program has raised hope and more than $2 million for metastatic breast cancer research.Here are links to #LightUpMBC resources:www.lightupmbc.orghttps://www.instagram.com/lightupmbc/https://www.instagram.com/metavivor/After 20 years in media sales leadership at Condé Nast and Hearst, holding roles like Associate Publisher of Marie Claire and Teen Vogue, Tami's life changed at 41 when she was diagnosed de novo with Stage IV metastatic breast cancer while raising two young children.She transformed her energy into advocacy, creating #LightUpMBC LIVE, She also co-produces The Janice Jam, Broadway for Breast Cancer, and has been featured on Good Morning America, The Today Show, and beyond. She's here to share her journey of resilience, advocacy, and creativity.From Publishing to Purpose: Tami, you spent two decades leading in the media world. Can you share what skills and experiences from that career you drew upon when shifting your energy into advocacy and creating #LightUpMBC LIVE?The Power of Visibility: Close to 300 landmarks across 166+ cities around the world will be illuminated on Metastatic Breast Cancer Awareness Day on October 13 as part of the incredible global campaign. How are landmark owners joining the #LightUpMBC campaign by lighting in the symbolic MBC colors of green, teal and pink on October 13? Why is visibility — literally lighting up the world — such a powerful metaphor and tool for raising awareness and hope in the MBC community?Patient Voices & Advocacy: You've said your mission is to amplify patient voices. What are some of the most important stories and lessons you've witnessed through the livestreams and advocacy work that you think the wider world needs to hear?Survive and Thrive: You've been honored with awards and legislative recognition for your impact. But beyond the spotlight, what does “survive and thrive” mean to you personally, as a mother, a patient, and a leader?The Eagle Method: You've created The Eagle Method as a framework to build resilience, embrace uncertainty, and improve mental health. Can you walk us through what it is, and how you apply it in your own life and with others?Tami, what's one piece of advice you would share with someone facing uncertainty or adversity about finding their voice and turning it into something that helps others?Connect with Tami at Tami's Website , and @EagleMethod on Instagram Thanks to our sponsor, White Cloud Coffee, fueling creative conversations everywhere. Listeners, enjoy 10% off your first order at whitecloudcoffee.com.And before you go, don't forget to download your free e-book of Your World of Creativity when you visit mark-stinson.com.

Featuring an interview with Prof Peter Schmid, including the following topics: Response to immunotherapy in breast cancer subtypes (0:00) Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51) Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03) ADC structure and treatment-related adverse events (19:02) Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06) Novel ADCs and bispecific antibodies under investigation for mBC (28:30) Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01) Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06) CME information and select publications

HEADLINES:♦ Saudi PIF Becomes Largest Shareholder in MBC in SAR 7.47 Billion Deal♦ Khalaf Al Habtoor Pledges $2.7M for Umayyad Mosque and Syrian Community♦ Red Sea Global Says Alcohol Not Needed for Luxury Tourism Success♦ Germany Still Weighing EU Sanctions on Israel  Newsletter: https://aug.us/4jqModrWhatsApp: https://aug.us/40FdYLUInstagram: https://aug.us/4ihltzQTiktok: https://aug.us/4lnV0D8Smashi Business Show (Mon-Friday): https://aug.us/3BTU2MY

Living with metastatic breast cancer is exhausting—physically, mentally, emotionally, and socially. It never takes a day off, and sometimes you just wish you could too. In this episode of I'm Still Here: Lessons from Life with Metastatic Breast Cancer, Heather explores the very real longing to take a “vacation” from MBC.You'll hear why the constant weight of appointments, scanxiety, side effects, and even other people's expectations can feel overwhelming—and why it's perfectly normal to want a break. More importantly, you'll discover small but powerful ways to give yourself permission to rest, escape, and find peace, even if cancer never fully leaves the room.

Featuring an interview with Dr Sarah Sammons, including the following topics: Development of brain metastases in patients with HER2-positive and HER2-negative breast cancer (0:00) Local therapy approaches for the treatment of brain metastases (8:23) Treatment options for patients with HER2-positive breast cancer and CNS-only disease progression (16:36) Clinical presentation of leptomeningeal disease; management of functional sequelae associated with brain metastases (19:07) Investigational agents for the treatment of brain metastases in HER2-positive breast cancer (25:01) Case: A 65-year-old woman with ER-negative, HER2-positive metastatic breast cancer (mBC) develops a single 6-mm brain metastasis after 4 years of maintenance trastuzumab/pertuzumab (27:38) Screening for brain metastases; radiation necrosis as a side effect of radiation therapy (31:00) Case: A 39-year-old woman with ER-negative, HER2-positive mBC develops 7 new brain metastases 6 months into treatment with a taxane, trastuzumab and pertuzumab (34:30) CME information and select publications

Meet Nour Al Din Al Youssef — one of the most recognized media personalities in the Arab world. Nour began his television journey at just 13 years old and quickly rose to fame through his dynamic presence on major networks like Dubai TV, Al Jazeera, MBC, Alhurra, Sama Dubai, and Abu Dhabi TV.Don't miss this conversation with a true pioneer of Gulf media — blending tradition with innovation, storytelling with purpose.Subscribe for more inspiring profiles and exclusive podcast episodes.#hikmatwehbipodcast #podcast#arabicpodcast #nouraldin#wstudiodxbحكمت_وهبي#حكمت_وهبي_بودكاست#

Join here for expert analysis of the latest clinical trial data in HR-positive MBC and discussion of the clinical implications of these study results. Credit available for this activity expires: 8/18/2026  Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002835?ecd=bdc_podcast_libsyn_mscpedu

Labhraímid le hEmmet Ryan faoina chlár faisnéise 'Sióga' faoin gclub cispheile LADTA+ Shamrock Sióga, éide scoile, AI, Wendy's agus Taco Bell ag oscailt in Éirinn agus Gavin Newsom ag éirí níos fíochmhaire le Trump. Beidh Sióga ar taispeáint san Outhouse i mBÁC ag a 7pm inniu agus an clár ag dul amach (Dé hAoine 22 Lúnasa) agus is féidir breathnú air ar Youtube ag an nasc seo freisin: https://www.youtube.com/watch?v=wDtww-Wh3fw&ab_channel=BallinEurope

1-2부 [뉴스신세계] 1. 김건희, 구속 후 세번째 특검 출석…특검 "진술거부권 행사" 2. 조국, 252일 만에 복당…'혁신정책연구원장' 지명 3. MBC 지배구조 개편 ‘방문진법' 개정안, 국회 본회의 통과 - 헬마우스 임경빈 작가(출연) [거침없이 하이킥] 김건희 발언 파장부터 통일교 의혹까지, 여권 흔드는 변수들 - 신인규 변호사 - 장성철 공론센터 소장 (출연)

3-4부 [주간정치동형] 조국 사면 이후, 이재명 정부 앞에 놓인 정치적 과제는? - 이동형 작가 (출연) [털어서 세계속으로] 러시아-우크라이나 전쟁, 종전 협상 향방은? - 권희진 MBC 기자 - 고한석 국제문제 전문가 (출연)

Doctor Eleonora Teplinsky is a board-certified medical oncologist who focuses on breast and gynecologic cancers. She is the head of breast and gynecologic medical oncology at Valley Mount Sinai Comprehensive Cancer Care in Paramus, NJ and is a Clinical Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.Doctor Teplinsky is passionate about working with young women facing breast cancer, especially when exploring things like survivorship, exercise, and how social media can play a role in cancer care. In this raw, refreshing, and beautifully honest episode, @wren_morr the founder of the Living Our Breast Lives Podcast is joined by the vibrant Dr. Teplinsky as she breaks down: 

What does it mean to be a disciple of Christ Jesus? MBC's world partner Clint Watkins dives into this subject as he preaches from the book of 2 Timothy. Here, he continues in week 2 of our sermon series "Summer in the Scriptures".

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics: Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00) Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49) Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44) Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29) Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19) CME information and select publications

1부 [JB TIMES] 尹 경호처, 용산 집무실 사우나 제작…'현금 거래' 제안 김건희 ‘日 왕실 납품' 진주 목걸이 착용…출처는? 건진, 윤영호에 ‘YTN 인수' 청탁 정황…”MBC 없애려 해” 尹, 내란재판 출석 못하지만 변호사 접견은 가능? 내란 특검, 한덕수 자택 압수수색…주목할 점은 당직자 폭행한 송언석 “강선우 의원직 사퇴해야” 대통령실 “전 정부 겨냥 과도한 정책감사 폐지” - 더 막내작가 [뉴스 채굴꾼] 김건희, 특검 조사 전 ‘아플 결심'하게 된다면? - 김연욱 작가

30th 경제콘서트 인공지능의 시대, 대한민국 반도체 산업의 생존전략 w. 김정호 카이스트 전기 및 전자공학과 교수 일시: 2025년 6월 28일 (토) 오후 2시 장소: 상암 MBC 골든마우스홀 출연: 김정호 카이스트 전기 및 전자공학과 교수, 이진우 기자

"In my mind, I'm not going anywhere anytime soon." It's been a whirlwind week. THANK YOU for all of the love, support, and kindness after last week's "we're due for a catch-up" episode. It's been an overwhelming time for me — but what about for my support squad? I get so many questions from people asking how best to show up for someone going through a hard time, and my team and I have learned a lot about what this can all look like. So for this one, Cousin Jackie returns, and we're talking about what the past few weeks have been like for each of us: the patient and the support person. SPONSORS:  Oofos: The best in recovery footwear! Check out Oofos's 2025 Project Pink collection, where 10% of every purchase is donated to cancer research.  Vuori: Click here for 20% off your first Vuori purchase. Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!